FDA approvals

FDA gives nod to Prandin generic

The FDA has granted tentative approval for the abbreviated new drug application for the generic version of Prandin, according to a press release.

Repaglinide (Prandin, Perrigo) belongs to the class of drugs known as meglitinides for the treatment of patients with type 2 diabetes. The brand name was first approved in 1997, and is currently available in 0.5-mg, 1-mg and 2-mg doses.

The FDA has granted tentative approval for the abbreviated new drug application for the generic version of Prandin, according to a press release.

Repaglinide (Prandin, Perrigo) belongs to the class of drugs known as meglitinides for the treatment of patients with type 2 diabetes. The brand name was first approved in 1997, and is currently available in 0.5-mg, 1-mg and 2-mg doses.